Tailored Radiotherapy for Clinically Node-negative Breast Cancer Patients with 1-2 Sentinel Node Macrometastases
A Multicenter Randomized Phase 3 Trial Comparing Regional Radiotherapy with De-escalated Treatment
Led by Region Skane · Updated on 2026-05-11
1350
Participants Needed
30
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether regional radiotherapy can be safely omitted in clinically node-negative breast cancer patients who have one or two sentinel node macrometastases and an estrogen receptor positive, HER2-negative tumor. This trial aims to improve quality of life and reduce side effects without worsening recurrence free survival at five years. The study is a randomized, multicenter, non-inferiority trial with a planned enrollment of 1350 patients.
Participants will be randomly assigned to receive either standard locoregional radiotherapy, which includes treatment to the remaining breast or chest wall and regional lymph nodes, or a de-escalated radiotherapy approach. In the intervention group, no lymph node irradiation is given radiotherapy is only delivered to the remaining breast after breast conserving surgery, and not after mastectomy unless there is widespread multifocality. Gene expression analyses will be performed for all patients to relate gene signatures to recurrence risk and radiotherapy benefit.
During the study, patients will be monitored through regular assessments to measure recurrence free survival at five years, which is the primary outcome. Secondary outcomes include locoregional and regional nodal recurrence, new contralateral breast cancer, distant recurrence free survival, overall survival, arm morbidity, and health-related quality of life. Follow-up will continue for at least five years to evaluate these outcomes and monitor safety and quality of life changes over time.
CONDITIONS
Brief Title
The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.
Research Team
S
Sara Alkner, Associate professor
T
T-REX Clinical Trials Office
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Primary unifocal or multifocal invasive breast cancer T1-T2
Clinically node negative (N0) status
Macrometastasis larger than 2 mm in 1-2 lymph nodes at sentinel node biopsy
Oral and written consent provided
Age 18 years or older
All surgical resection margins must be tumor free
Primary tumor must be estrogen receptor positive and HER2-negative
You will not qualify if you...
Regional or distant metastases outside the ipsilateral axilla
Previous radiotherapy towards the planned target area (ipsilateral chest or lymph nodes)
Neoadjuvant systemic therapy
Previous axillary lymph node dissection or surgery on the affected side
Prior history of invasive breast cancer
Pregnancy
Bilateral invasive breast cancer
Contraindications for radiotherapy or systemic treatment
Inability to understand or consent to the study (due to disability, language skills, or dementia)
Other invasive cancer within 5 years prior to breast cancer diagnosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 5 years of follow-up to assess outcomes
Participants receive tailored regional external beam radiotherapy or no regional radiotherapy after surgery depending on random assignment.
Visits scheduled according to radiotherapy and follow-up care protocols
Follow-up
Duration - Up to 5 years after treatment
Participants are monitored for recurrence, survival, morbidity, and quality of life after treatment.
Regular follow-up visits for monitoring over 5 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Studying Key Non-coding RNAs and Their Interaction With Chromatin Remodeling in Breast Cancer Patients
Comparing 18F-FDG and 68Ga-FAPI-46 PET Scans in Women With ER-positive Breast Cancer
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Study Comparing 3D-Printed Biodegradable Breast Implants, Traditional Breast-Conserving Surgery, and Silicone Implant Reconstruction for Breast Cancer Patients
Ultrahypofractionated 5-Session Whole Breast Radiotherapy with Boost versus Standard 15-Session Radiotherapy for Breast Cancer Patients with Unfavorable Characteristics
Phase II Study Comparing 5-Day vs. 9-Day Whole Breast Radiotherapy with Boost in Early-stage Breast Cancer
Evaluating 68Ga-FAPI PETCT for Checking Axillary Lymph Node Status After Neoadjuvant Therapy in Women with Breast Cancer
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases - an open, multicentre, randomised non-inferiority phase 3 trial.